Article

Ophtec Announces Modern New Brand Identity: Keeping Up with the Times

Author(s):

Celebrating 40-year anniversary with new brand/new products.

(Image Credit: AdobeStock/Blue Planet Studio)

(Image Credit: AdobeStock/Blue Planet Studio)

Ophtec, the Dutch manufacturer of intraocular lenses (IOLs) based in Groningen, is hitting the 40-year mark in 2023. To celebrate the event, the company is launching a new brand identity that is modernized and fit for the future, according to the company’s press release.

Marketing manager Remko Bos explains the reasons behind the rebranding, “Ophtec always had a full focus on making unique products. Our people are highly dedicated to support ophthalmologists to do their best job possible. Our branding was somehow underexposed. This year is a great moment for us to honor our heritage, fresh up our brand and connect to a new generation of eye-doctors.”

Bos describes the new brand as “quite a transformation,” with colors that catch the eye.

“New look, same focus, and an ingenious partner to ophthalmologists. Together, we help people to see clearly," said Bos.

Ophtec was founded in 1983 by Prof. Dr. Jan Worst, who invented the Artisan lens, the first iris-fixated IOL. To this day, the company remains family-owned.

“When my parents established Ophtec in 1983, it was their ambition to let surgeons and patients benefit from better products than were commonly available at the time,” Chief Executive Officer Erik Jan Worst commented. “And 40 years later we are still here. This makes me deeply proud and energized to lead the company into the future.”

The rebranding, which will become official on March 10, 2023, will be followed by the introduction of new products.

Worst announced the launch of ArtiPlus, a new iris-fixated presbyopia correction phakic IOL, in South Korea. A clinical study of the IOL is underway in Europe, and he described the results as “spectacular.”

Ophtec is also introducing a new pre-loaded injector system for the Precizon cataract lenses and after the summer the company expects to launch an exciting new lens concept.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.